Published in Crit Care on April 06, 2010
Antibiotic stewardship in the intensive care unit. Crit Care (2014) 1.18
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis (2014) 0.95
Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury. Indian J Crit Care Med (2015) 0.94
Advances in antibiotic therapy in the critically ill. Crit Care (2016) 0.94
Therapeutic drug monitoring of amikacin in septic patients. Crit Care (2013) 0.92
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 0.91
An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence (2013) 0.86
Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care (2014) 0.86
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol (2014) 0.85
Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother (2011) 0.83
Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother (2011) 0.82
Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. Curr Infect Dis Rep (2015) 0.81
Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol (2012) 0.80
Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients. Int J Crit Illn Inj Sci (2011) 0.80
Bloodstream infections in the Intensive Care Unit. Virulence (2016) 0.78
Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study. Eur J Pediatr (2016) 0.78
Amikacin pharmacokinetics during continuous veno-venous hemodialysis. Infect Dis Ther (2013) 0.77
Optimizing the Initial Amikacin Dosage in Adults. Antimicrob Agents Chemother (2015) 0.77
Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling. Antimicrob Agents Chemother (2016) 0.76
Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. J Clin Med Res (2014) 0.75
Year in review 2010: Critical Care--Infection. Crit Care (2011) 0.75
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. Ann Intensive Care (2016) 0.75
Optimal aminoglycoside therapy following the sepsis: how much is too much? Iran J Pharm Res (2013) 0.75
Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother (2016) 0.75
Application of guidelines for aminoglycosides use in French hospitals in 2013-2014. Eur J Clin Microbiol Infect Dis (2017) 0.75
Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care. Ann Intensive Care (2017) 0.75
A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis. Eur J Clin Microbiol Infect Dis (2016) 0.75
Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc (2015) 0.75
APACHE II: a severity of disease classification system. Crit Care Med (1985) 69.83
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med (1996) 35.00
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control (2008) 24.70
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 7.40
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev (2006) 3.13
Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med (2009) 3.09
Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet (2000) 2.69
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis (2004) 2.67
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med (1984) 2.54
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis (1984) 2.44
The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect (2003) 2.07
Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy (2007) 1.83
Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med (1990) 1.82
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet (1994) 1.59
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet (2005) 1.45
Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med (1996) 1.43
Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis (2007) 1.43
Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med (1990) 1.28
Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm (1980) 1.26
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother (1991) 1.25
Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care (2002) 1.23
Increased dosage requirements of gentamicin in burn patients. J Trauma (1976) 1.23
Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit (2008) 1.22
Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J (2011) 1.21
Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care (1993) 1.21
Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm (1986) 1.19
Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med (2002) 1.18
Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother (2003) 1.16
Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother (1995) 1.15
Old antibiotics for infections in critically ill patients. Curr Opin Crit Care (2007) 1.14
Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med (2003) 1.14
Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib Nephrol (2007) 1.04
The accuracy of visual estimation of body weight in the ED. Am J Emerg Med (2004) 1.01
The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother (1991) 1.00
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother (2003) 0.97
Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med (1997) 0.87
Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother (1987) 0.86
Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm (1993) 0.81
[Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight]. Therapie (2009) 0.81
Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother (2000) 0.78
Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance. J Clin Pharm Ther (2008) 0.77
Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Intensive Care Med (1995) 0.77
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med (2013) 17.37
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med (2015) 10.15
Mortality after surgery in Europe: a 7 day cohort study. Lancet (2012) 9.96
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med (2010) 8.58
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med (2004) 5.90
Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med (2002) 5.84
Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA (2010) 5.80
Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology (2015) 5.52
Circulatory shock. N Engl J Med (2013) 4.95
Sepsis biomarkers: a review. Crit Care (2010) 4.76
Incidence and prognosis of intraabdominal hypertension in a mixed population of critically ill patients: a multiple-center epidemiological study. Crit Care Med (2005) 4.61
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis (2006) 4.29
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med (2003) 4.04
Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med (2005) 3.97
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. Intensive Care Med (2005) 3.81
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med (2006) 3.53
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med (2014) 3.37
Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med (2011) 3.34
Fluid challenges in intensive care: the FENICE study: A global inception cohort study. Intensive Care Med (2015) 3.27
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med (2014) 3.17
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Management of bleeding following major trauma: an updated European guideline. Crit Care (2010) 3.09
Microvascular response to red blood cell transfusion in patients with severe sepsis. Crit Care Med (2007) 3.06
C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest (2003) 2.95
Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest (2008) 2.90
Let us use the pulmonary artery catheter correctly and only when we need it. Crit Care Med (2005) 2.83
Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma (2010) 2.82
Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am J Respir Crit Care Med (2014) 2.78
Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med (2006) 2.74
Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest (2003) 2.73
Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med (2005) 2.73
Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med (2013) 2.72
Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis. Crit Care Med (2009) 2.68
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Prevalence of intra-abdominal hypertension in critically ill patients: a multicentre epidemiological study. Intensive Care Med (2004) 2.56
Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg (2007) 2.55
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med (2003) 2.54
Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea. Intensive Care Med (2012) 2.52
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48
Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med (2006) 2.47
Sublingual capnometry tracks microcirculatory changes in septic patients. Intensive Care Med (2006) 2.40
Ethics and end-of-life care for adults in the intensive care unit. Lancet (2010) 2.40
Management of bleeding following major trauma: a European guideline. Crit Care (2007) 2.40
Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med (2012) 2.39
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc (2011) 2.38
Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med (2004) 2.33
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med (2008) 2.27
The prognostic value of muscle StO2 in septic patients. Intensive Care Med (2007) 2.25
Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med (2003) 2.23
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis (2004) 2.22
Gamma-globulin levels in patients with community-acquired septic shock. Shock (2009) 2.21
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis (2004) 2.17
A large-bolus injection, but not continuous infusion of sodium selenite improves outcome in peritonitis. Shock (2009) 2.17
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock (2014) 2.11
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med (2010) 2.11
Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion (2009) 2.11